secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2026-09-21T20:30:15+00:00
Accession:  0001193125-26-396716
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

European Commission approves obicetrapib (Ubeslo/Evlarco) for hypercholesterolaemia; first approval worldwide
--------------------------------------------------------------------------------

- EC granted marketing authorization for Ubeslo (obicetrapib 10mg) and Evlarco (obicetrapib+ezetimibe FDC) for primary hypercholesterolaemia or mixed dyslipidaemia; first global approval.
- Authorizations cover all EU states plus Iceland, Liechtenstein, Norway; require post-authorization efficacy study, including final PREVAIL outcomes trial results.
- Menarini holds exclusive EU commercialization rights; NewAmsterdam receives tiered double-digit royalties (low double-digits to mid-twenties %) on net sales.
- Up to €833M in milestones; mid-teens of millions euros triggered directly by these EC approvals for obicetrapib and the FDC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526396716/0001193125-26-396716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312526396716/nams-20260921.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-396716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer